RecruitingNot ApplicableNCT06695221

Improving Health Outcomes With Kefir

Sponsor

University of Alberta

Enrollment

156 participants

Start Date

Mar 24, 2026

Study Type

INTERVENTIONAL

Conditions

Cardiovascular Diseases Diabetes Mellitus, Type 2 Systemic Inflammatory Response

Summary

The purpose of the study is to ascertain whether traditional kefir not only enhances vascular health but also contributes to improved immune outcomes in both male and female participants at higher risk or living with Type 2 Diabetes (T2D) after 12 weeks of treatment.

Eligibility

Min Age: 24 YearsMax Age: 70 Years

Inclusion Criteria4

females and males (24-70 years old) living in Edmonton (or Edmonton area/driving distance);
overweight or obesity (BMI \>25 Caucasian, \>23 Asian);
at higher risk of T2D (fasting blood glucose ≥ 5.6 - 6.9 mmol/L or/and HbA1C ≥ 5.5 - 6.4%); or
with diagnosis of T2D (fasting blood glucose ≥ 7.0 mmol/L or/and HbA1C ≥ 6.5%).

Exclusion Criteria7

a usual high intake (maximum intake 3 servings/week) of fermented foods excluding cheese (i.e., kefir, kombucha, kimchi, etc.) for the past 3 months;
gastrointestinal (GI) disorders of any kind;
being pregnant or breastfeeding;
monogenic dyslipidemias and endocrine disorders except for diabetes;
use of medications within the last 3 months (i.e., antibiotics or antifungals, corticosteroids, methotrexate, or immunosuppressive cytotoxic agents);
any health conditions deemed to interfere with primary outcomes at the investigator's discretion (e.g., kidney disease, liver disease, cancer, GI surgery, heavy alcohol consumption, etc.);
having a pacemaker or any electrical medical device that prevents the individual from undergoing the bioelectrical impedance analysis bioimmunoassay (BIA) test."